Transcriptional profiling of antidepressant ketamine and electroconvulsive therapy treatment
medRxiv July 29, 2025 Artemis Zavaliangos-Petropulu, Ginny Ghang, Toni Boltz et al. preprint
Background: Treatment-resistant depression (TRD) affects 30-50% of patients with major depressive disorder (MDD). Electroconvulsive therapy (ECT) and sub-anesthetic ketamine treatment can relieve TRD, yet their antidepressant mechanisms remain unclear. Peripheral blood gene expression offers a non-invasive proxy to examine potential treatment-response biomarkers. Methods: We conducted a...
DOI: 10.1101/2025.07.29.25332162 (opens in new tab)
Full text (opens in new tab)
Ketamine
Electroconvulsive therapy
Antidepressant
Profiling computer programming
+3